The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.
The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh ... third FDA-approved biosimilar of Actemra and will be available in both intravenous (IV) and subcutaneous ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for ...
FDA approved another biosimilar to tocilizumab (Actemra), branded as Avtozma, for the intravenous or subcutaneous treatment of rheumatoid arthritis, COVID-19, and other tocilizumab-approved ...
As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis. The FDA recently approved ...
The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...
tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA ®. AVTOZMA is indicated for the treatment of multiple diseases including rheumatoid arthritis ...
The European Commission has approved the first biosimilar version of Actemra/RoActemra ... offering of both intravenous and subcutaneous formulations of tocilizumab and is targeting the number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results